HCA
HRMY icon

Heck Capital Advisors’s Harmony Biosciences HRMY Stock Holding History

Heck Capital Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$17.2K – 486
2024
Q4 		$17.2K Buy
+500
New +$17.2K ﹤0.01% 493

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Heck Capital Advisors's HRMY Position: Q1 2025 in Review

Heck Capital Advisors sold out of Harmony Biosciences (HRMY) in Q1 2025, closing a stake of 500 shares — an estimated $17.2K sold.

Heck Capital Advisors first reported a position in HRMY in Q4 2024 and held it in 1 quarter. The position peaked at $17.2K in Q4 2024. 272 funds tracked by Wall St. Rank hold HRMY as of Q1 2025.

  • Heck Capital Advisors reported no remaining Harmony Biosciences position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 500 Harmony Biosciences shares in Q1 2025, an estimated $17.2K.
  • Heck Capital Advisors first reported a position in Harmony Biosciences in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's Harmony Biosciences position peaked at $17.2K in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.